LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $38.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Raymond James began coverage on LENZ Therapeutics in a report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective for the company. William Blair raised LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Piper Sandler reissued an “overweight” rating and set a $36.00 price target on shares of LENZ Therapeutics in a report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Trading Up 7.8 %

LENZ opened at $35.07 on Thursday. The business’s 50-day moving average price is $24.94 and its 200-day moving average price is $21.24. LENZ Therapeutics has a 12 month low of $14.07 and a 12 month high of $37.13.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same period in the prior year, the company posted ($1.33) EPS. On average, equities analysts forecast that LENZ Therapeutics will post -3.15 earnings per share for the current fiscal year.

Institutional Trading of LENZ Therapeutics

Several large investors have recently bought and sold shares of LENZ. American International Group Inc. acquired a new stake in LENZ Therapeutics during the first quarter valued at $44,000. SG Americas Securities LLC purchased a new position in shares of LENZ Therapeutics in the third quarter valued at approximately $107,000. Squarepoint Ops LLC acquired a new stake in LENZ Therapeutics during the 2nd quarter worth $181,000. GSA Capital Partners LLP purchased a new stake in LENZ Therapeutics during the 3rd quarter valued at about $246,000. Finally, Rhumbline Advisers increased its holdings in shares of LENZ Therapeutics by 265.6% in the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock valued at $291,000 after purchasing an additional 12,214 shares during the last quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.